As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…
This podcast episode is sponsored by AVEO Oncology. The product information in this podcast is intended only for US residents. This episode features a real patient and their care partner,…
According to an article recently published in Clinical Trials Arena, the Swedish pharmaceutical company Oncorena has recently initiated a Phase I/II trial for orellanine. This investigational treatment is intended for…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
